Медуллобластома (МБ) является наиболее распространенной эмбриональной опухолью центральной нервной системы, хотя общий показатель излечения составляет около 70%, у больных, страдающих этим заболеванием, исходы неблагоприятны, а продолжительность заболевания сохраняется длительное время.

классификация, диагностика, гистология, медуллобластома, SHH, WNT.

Andrey K, Felix S, Olga Z, Andrey G, Damian S, Daniel S et al (2019) DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. Neuro-Oncology 21:214–221.

Andrey K, Lukas C, Northcott PA, Tanvi S, Marina R, Jones DTW et al (2017) DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. Acta Neuropathol 134:965–967.

Arceci RJ (2010) Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. Yearb Oncol 28:203–204.

Bailey P (1925) Medulloblastoma cerebelli. Arch Neurol Psychiatry 14:192–224.

Bailey P, Cushing H (1926) A Classification of the Tumors of the Glioma Group on a Histogenetic Basis With a Correlated Study of Prognosis. Lippincott: Philadelphia.

Bailey CC, Gnekow A, Wellek S, Jones M, Round C, Brown J et al (1995) Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International society of paediatric oncology (SIOP) and the (German) society of paediatric oncology (GPO): SIOP II. Med Pediatr Oncol 25:166–178.

Brown HG, Kepner JL, Perlman EJ, Friedman HS, Strother DR, Duffner PK et al (2000) “Large cell/anaplastic” medulloblastomas: a pediatric oncology group study. J Neuropathol Exp Neurol 59:857–865.

Capper D, Jones DT, Sill M, Hovestadt V, Schrimpf D, Sturm D et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469–474.

Cavalli FM, Remke M, Rampasek L, Peacock J, Shih DJ, Luu B et al (2017) Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31:737–754.e6.

Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H et al (2011) Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29:1424–1430.

Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D, Ellison DW (2006) Wnt/ Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 5:2666–2670.

Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK, Friedman HS et al (2002) Histopathologic grading of medulloblastomas. Cancer 94:552–560.

Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G et al (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121:381–396.

Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL et al (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29:1400–1407.

Farwell JR, Dohrmann GJ, Flannery JT (1984) Medulloblastoma in childhood: an epidemiological study. J Neurosurg 61:657–664.

Ferguson S, Lesniak MS (2005) Percival Bailey and the classification of brain tumors. Neurosurg Focus 18:1–6.

Fernandez LA, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S et al (2009) YAP1 is amplified and upregulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev 23:2729–2741.

Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway Det al (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26:317–325.

Giangaspero F, Perilongo G, Fondelli MP, Brisigotti M, Carollo C, Burnelli R et al (1999) Medulloblastoma with extensive nodularity: a variant with favorable prognosis. J Neurosurg 91:971–977.

Giangaspero F, Rigobello L, Badiali M, Loda M, Andreini L, Basso G et al (1992) Large-cell medulloblastomas. Am J Surg Pathol 16:687–693.

Giangaspero F, Wellek S, Masuoka J, Gessi M, Kleihues P, Ohgaki H (2006) Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol 112:5–12.

Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C et al (2010) Subtypes of medulloblastoma have distinct developmental origins. Nature 468:1095–1099.

Gilbertson Richard J, Ellison David W (2008) The origins of medulloblastoma subtypes. Annu Rev Pathol 3:341–365.

Goschzik T, Schwalbe EC, Hicks D, Smith A, zur Muehlen A, Figarella-Branger D et al (2018) Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. Lancet Oncol 19:1602–1616.

Helton KJ, Fouladi M, Boop FA, Perry A, Dalton J, Kun L, Fuller C (2004) Medullomyoblastoma: a radiographic and clinicopathologic analysis of six cases and review of the literature. Cancer 101:1445–1454.

Hovestadt V, Remke M, Kool M, Pietsch T, Northcott PA, Fischer R et al (2013) Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 125:913–916.

Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M et al (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488:100–105.

King AA, Seidel K, Di C, Leisenring WM, Perkins SM, Krull KR et al (2017) Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. Neuro Oncol 19:689–698.

Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V et al (2014) Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25:393–405.

Kool M, Korshunov A, Remke M, Jones DTW, Schlanstein M, Northcott PA et al (2012) Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123:473–484.

Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P et al (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 3:e3088.

Korshunov A, Ryzhova M, Jones DTW, Northcott PA, van Sluis P, Volckmann R et al (2012) LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol 124:875–881.

Leonard JR, Cai DX, Rivet DJ, Kaufman BA, Park TS, Levy BK, Perry A (2001) Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J Neurosurg 95:82–88.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109.

Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A et al (2014) International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24:429–435.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820.

McManamy CS, Lamont JM, Taylor RE, Cole M, Pearson AD J, Clifford SC, Ellison DW (2003) Morphophenotypic variation predicts clinical behavior in childhood nondesmoplastic medulloblastomas. J Neuropathol Exp Neurol 62:627–632.

McManamy CS, Pears J, Weston CL, Hanzely Z, Ironside JW, Taylor RE et al (2007) Nodule formation and desmoplasia in medulloblastomas—defining the nodular/ desmoplastic variant and its biological behavior. Brain Pathol 17:151–164.

Merchant TE, Pollack IF, Loeffler JS (2010) Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol 20:58–66.